Comparing Audentes Therapeutics (BOLD) and Pieris Pharmaceuticals (PIRS)
Audentes Therapeutics (NASDAQ: BOLD) and Pieris Pharmaceuticals (NASDAQ:PIRS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.
Volatility and Risk
Audentes Therapeutics has a beta of -0.86, indicating that its stock price is 186% less volatile than the S&P 500. Comparatively, Pieris Pharmaceuticals has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500.
This is a breakdown of current recommendations for Audentes Therapeutics and Pieris Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Audentes Therapeutics currently has a consensus target price of $22.25, indicating a potential downside of 13.59%. Pieris Pharmaceuticals has a consensus target price of $8.25, indicating a potential upside of 51.93%. Given Pieris Pharmaceuticals’ higher possible upside, analysts plainly believe Pieris Pharmaceuticals is more favorable than Audentes Therapeutics.
Institutional and Insider Ownership
77.0% of Audentes Therapeutics shares are held by institutional investors. Comparatively, 50.5% of Pieris Pharmaceuticals shares are held by institutional investors. 47.3% of Audentes Therapeutics shares are held by company insiders. Comparatively, 4.1% of Pieris Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Audentes Therapeutics and Pieris Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Audentes Therapeutics||N/A||N/A||-$73.43 million||($3.55)||-7.25|
|Pieris Pharmaceuticals||$6.71 million||35.86||-$27.99 million||($0.72)||-7.54|
Pieris Pharmaceuticals has higher revenue and earnings than Audentes Therapeutics. Pieris Pharmaceuticals is trading at a lower price-to-earnings ratio than Audentes Therapeutics, indicating that it is currently the more affordable of the two stocks.
This table compares Audentes Therapeutics and Pieris Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Pieris Pharmaceuticals beats Audentes Therapeutics on 6 of the 11 factors compared between the two stocks.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company’s subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company’s second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.
Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.